Results 31 to 40 of about 72,428 (200)

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

BMC Cancer, 2017
Background Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear.
Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, Le-Qun Li   +9 more
doaj   +1 more source

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. [PDF]

PLoS ONE, 2013
The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC).
Wei-Chien Huang, Yi-Ling Hsieh, Chao-Ming Hung, Pei-Hsuan Chien, Yu-Fong Chien, Lei-Chin Chen, Chih-Yen Tu, Chia-Hung Chen, Sheng-Chieh Hsu, Yueh-Ming Lin, Yun-Ju Chen   +10 more
doaj   +1 more source

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). [PDF]

PLoS ONE, 2014
Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event. This study aimed to examine whether the toxicity of sorafenib and sunitinib for human keratinocytes was associated with inhibiting signal transduction and activator of
Kazuhiro Yamamoto, Atsushi Mizumoto, Kohji Nishimura, Atsushi Uda, Akira Mukai, Kazuhiko Yamashita, Manabu Kume, Hiroo Makimoto, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano, Midori Hirai   +12 more
doaj   +1 more source

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

JAMA Oncology, 2020
Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib?
T. Yau, Yoon-Koo Kang, Tae-You Kim, A. El-Khoueiry, A. Santoro, B. Sangro, I. Melero, M. Kudo, M. Hou, A. Matilla, F. Tovoli, J. Knox, A. Ruth He, B. El-Rayes, M. Acosta-Rivera, Ho Yeong Lim, J. Neely, Yun Shen, T. Wisniewski, Jeffrey Anderson, Chiun Hsu   +20 more
semanticscholar   +1 more source

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

Liver Cancer, 2022
Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS ...
M. Kudo, K. Ueshima, M. Ikeda, T. Torimura, N. Tanabe, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, T. Kuzuya, N. Isoda, M. Moriguchi, Hajime Aino, A. Ido, Naoto Kawabe, K. Nakao, Y. Wada, S. Ogasawara, K. Yoshimura, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, P. Johnson, Y. Arai   +26 more
semanticscholar   +1 more source

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Signal Transduction and Targeted Therapy, 2020
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately,
Weiwei Tang, Ziyi Chen, Wenling Zhang, Ye Cheng, Betty Zhang, Fan Wu, Qian Wang, Shouju Wang, D. Rong, F. Reiter, E. Toni, Xuehao Wang   +11 more
semanticscholar   +1 more source

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Journal of Clinical Oncology, 2021
PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies.
S. Qin, F. Bi, S. Gu, Y. Bai, Zhendong Chen, Zishu Wang, J. Ying, Yinying Lu, Z. Meng, H. Pan, Ping Yang, He-long Zhang, Xi Chen, A. Xu, C. Cui, B. Zhu, Jian Wu, Xiao-ming Xin, Jufeng Wang, Jin-lu Shan, Junhui Chen, Zhendong Zheng, Li Xu, X. Wen, Z. You, Z. Ren, Xiufeng Liu, M. Qiu, Liqing Wu, F. Chen   +29 more
semanticscholar   +1 more source

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

Journal of Clinical Oncology, 2020
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently ...
A. Burchert, G. Bug, Lea Fritz, J. Finke, M. Stelljes, C. Röllig, E. Wollmer, R. Wäsch, M. Bornhäuser, T. Berg, F. Lang, G. Ehninger, H. Serve, R. Zeiser, E. Wagner, N. Kröger, C. Wolschke, M. Schleuning, K. Götze, C. Schmid, M. Crysandt, Eva Esseling, D. Wolf, Ying Wang, A. Böhm, C. Thiede, T. Haferlach, Christian Michel, W. Bethge, T. Wündisch, C. Brandts, Susanne Harnisch, M. Wittenberg, H. Hoeffkes, Susanne Rospleszcz, A. Burchardt, A. Neubauer, Markus Brugger, K. Strauch, C. Schade-Brittinger, S. Metzelder   +40 more
semanticscholar   +1 more source